AU2001268710A1 - Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy - Google Patents

Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy

Info

Publication number
AU2001268710A1
AU2001268710A1 AU2001268710A AU6871001A AU2001268710A1 AU 2001268710 A1 AU2001268710 A1 AU 2001268710A1 AU 2001268710 A AU2001268710 A AU 2001268710A AU 6871001 A AU6871001 A AU 6871001A AU 2001268710 A1 AU2001268710 A1 AU 2001268710A1
Authority
AU
Australia
Prior art keywords
pharmaceuticals
imaging
combination therapy
angiogenic disorders
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268710A
Other languages
English (en)
Inventor
John A Barrett
Alan P. Carpenter Jr.
D. Scott Edwards
Stuart J. Heminway
Shuang Liu
Milind Rajopadhye
Prahlad Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2001268710A1 publication Critical patent/AU2001268710A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
AU2001268710A 2000-06-21 2001-06-21 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy Abandoned AU2001268710A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21320600P 2000-06-21 2000-06-21
US60/213,206 2000-06-21
PCT/US2001/020108 WO2001097860A2 (en) 2000-06-21 2001-06-21 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy

Publications (1)

Publication Number Publication Date
AU2001268710A1 true AU2001268710A1 (en) 2002-01-02

Family

ID=22794144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268710A Abandoned AU2001268710A1 (en) 2000-06-21 2001-06-21 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy

Country Status (5)

Country Link
EP (1) EP1311302A2 (ja)
JP (1) JP2005538030A (ja)
AU (1) AU2001268710A1 (ja)
CA (1) CA2413328A1 (ja)
WO (1) WO2001097860A2 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
MXPA02012750A (es) * 2000-06-21 2004-07-30 Bristol Myers Squibb Pharma Co Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion.
WO2001097861A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2448562A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
ES2398393T3 (es) * 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2008090731A1 (ja) 2007-01-23 2008-07-31 Pola Pharma Inc. ２－ニトロイミダゾール誘導体の製造法
LT2528602T (lt) 2010-01-28 2017-02-27 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
KR101769911B1 (ko) 2015-11-09 2017-08-21 포항공과대학교 산학협력단 신규한 항암제로서 Skp2 저해제
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
AU2019382881A1 (en) 2018-11-23 2021-05-20 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015884B1 (en) * 1997-09-10 2008-08-06 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
EA200001007A1 (ru) * 1998-03-31 2001-04-23 Дюпон Фармасьютикалз Компани Фармацевтические препараты для визуализации ангиогенных расстройств
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof

Also Published As

Publication number Publication date
WO2001097860A2 (en) 2001-12-27
CA2413328A1 (en) 2001-12-27
WO2001097860A3 (en) 2003-02-27
JP2005538030A (ja) 2005-12-15
EP1311302A2 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2001268710A1 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AU2002245629A1 (en) Stabilized therapeutic and imaging agents
IL138093A0 (en) Pharmaceuticals for the imaging of angiogenic disorders
SI1757606T1 (sl) Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
PL351526A1 (en) Pharmaceutical formulation comprising amoxycillin
AU2001252135A1 (en) Therapeutic agents
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
AU1164601A (en) Therapeutic use and formulation
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2001243515A1 (en) Combination drug therapy
AU2451500A (en) Therapeutic agents
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2001273903A1 (en) Therapeutic agents
AU5973600A (en) Therapeutic agents
AU2001272552A1 (en) Oxygen-enriched agent and the use thereof for therapeutic purposes
AUPQ475499A0 (en) Phosphoglycerate kinase in the treatment of disease
AU2002312779A1 (en) Delta-aminolevulinic acid for the therapeutical and cosmetic use
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
GB9911238D0 (en) Therapeutic use
AU3245101A (en) Device for supporting the human body
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
AU3808800A (en) Compounds for use in therapy
AU3025800A (en) Support device for the human body
AU5817500A (en) Therapeutic agents